abil
comprehens
character
exposur
immun
respons
viral
infect
critic
better
understand
human
health
diseas
previous
describ
virscan
system
phagedisplay
base
technolog
profil
antibodi
bind
comprehens
librari
peptid
design
repres
human
virom
previou
virscan
analyt
approach
fulli
account
disproportion
represent
virus
librari
antibodi
crossreact
among
sequenc
share
relat
virus
present
antivir
antibodi
respons
deconvolut
algorithm
avarda
multimodul
softwar
packag
analyz
virscan
dataset
avarda
provid
probabilist
assess
infect
specieslevel
resolut
consid
align
librari
peptid
human
virus
employ
avarda
analyz
virscan
data
cohort
enceph
patient
either
known
viral
infect
undiagnos
etiolog
compar
acut
convalesc
sera
avarda
success
confirm
detect
antibodi
respons
human
herpesvirus
therebi
improv
rate
diagnos
viral
enceph
cohort
assess
avarda
util
set
epidemiolog
studi
demonstr
abil
determin
infect
acquir
child
follow
prospect
infanc
consid
way
avarda
conceptu
framework
may
develop
futur
describ
analys
may
extend
beyond
investig
viral
infect
avarda
combin
virscan
panpathogen
serolog
techniqu
like
find
broad
util
epidemiolog
diagnosi
infecti
diseas
right
reserv
reus
allow
without
permiss
comprehens
profil
viromewid
antibodi
bind
specif
broad
util
epidemiolog
investig
surveil
emerg
virus
unbias
diagnosi
infect
phage
immunoprecipit
sequenc
phipseq
peptid
librari
span
human
virom
virscan
provid
platform
unbias
highthroughput
low
cost
analysi
antivir
antibodi
multiplex
serolog
techniqu
exist
limit
represent
viral
antigen
size
qualiti
epitop
present
persampl
assay
cost
andor
sampl
throughput
virscan
provid
favor
perform
characterist
interpret
assay
result
limit
rudimentari
analyt
framework
previous
publish
analyt
approach
suffer
three
critic
limit
first
number
nonoverlap
virusassoci
antibodi
specif
measur
respons
breadth
convey
import
biolog
inform
inform
confid
predict
exposur
nonoverlap
specif
defin
use
suboptim
heurist
typic
underestim
respons
breadth
second
significantli
enrich
peptid
consid
context
specif
viru
design
repres
ignor
sequenc
homolog
relat
virus
potenti
antibodi
crossreact
virscan
librari
design
cover
singl
repres
protein
uniprot
cluster
ident
reli
sole
upon
intend
viral
represent
enrich
peptid
diagnos
infect
therefor
result
fals
neg
result
miss
peptid
true
infect
organ
fals
posit
result
peptid
enrich
due
crossreact
antibodi
third
previous
reli
viru
proteom
size
establish
virusspecif
threshold
seroposit
approach
ignor
proport
represent
viru
within
enrich
set
peptid
correspond
virusspecif
represent
librari
addit
use
threshold
seroposit
far
less
inform
probabilist
assess
viral
infect
introduc
antivir
antibodi
respons
deconvolut
algorithm
avarda
analyt
framework
improv
analysi
massiv
multiplex
antivir
antibodi
bind
data
avarda
integr
three
key
modul
gener
conserv
probabilist
assess
current
histor
viral
exposur
first
modul
employ
network
graph
base
peptidepeptid
relationship
defin
minimum
number
independ
antibodi
specif
ie
respons
breadth
requir
complet
explain
set
observ
enrich
peptid
second
modul
use
sequenc
align
defin
peptid
relationship
comprehens
databas
human
viral
genom
translat
six
read
frame
permit
conserv
consider
viral
infect
could
potenti
elicit
observ
antibodi
specif
convers
set
peptid
enrich
could
potenti
associ
viru
third
modul
iter
assign
peptid
like
associ
viral
infect
accord
null
model
consid
represent
viru
virscan
librari
approach
permit
peptid
associ
multipl
distinct
infect
provid
suffici
evid
viral
infect
ie
absenc
share
peptid
avarda
also
indic
uncertainti
peptideviru
assign
insuffici
evid
discrimin
infect
relat
viral
candid
enough
evid
conclud
infect
inde
occur
link
modul
final
output
avarda
provid
multipl
hypothesi
adjust
pvalu
exposur
viru
along
associ
breadth
antibodi
respons
relationship
enrich
peptid
util
antibodybas
diagnost
constrain
inabl
robustli
discrimin
among
infect
close
relat
viral
pathogen
import
exampl
challeng
distinguish
flaviviru
infect
notabl
set
recent
zika
viru
outbreak
unbias
analysi
antivir
antibodi
use
robust
algorithm
comprehens
consid
potenti
crossreact
dramat
improv
clinic
util
antibodi
analys
singl
timepoint
test
igg
reactiv
difficult
interpret
context
ongo
recent
infect
antibodi
may
due
long
live
plasma
cell
induc
histor
infect
quantifi
individu
chang
igg
specif
time
howev
may
provid
clearer
evid
evolv
immun
respons
similarli
compar
igg
specif
across
distinct
physiolog
compart
may
provid
evid
organspecif
infect
eg
blood
versu
cerebrospin
fluid
set
enceph
pairwis
virscan
comparison
would
particularli
problemat
previou
analyt
approach
low
number
high
proport
chang
peptid
may
observ
respons
singl
infect
ii
ongo
antibodi
respons
may
associ
broadli
crossreact
antibodi
therefor
develop
avarda
algorithm
use
pairwis
virscan
data
gener
longitudin
patient
viral
enceph
predict
algorithm
found
agre
clinic
nucleic
acid
serolog
test
case
addit
util
virscanavarda
analysi
conjunct
tradit
nucleic
acid
test
result
increas
diagnosi
viral
enceph
final
demonstr
util
avarda
epidemiolog
investig
determin
childhood
infect
acquir
set
longitudin
cohort
studi
perform
virscan
analysi
pair
sera
obtain
encephal
cohort
collect
upon
initi
hospit
admiss
fourteen
day
postadmiss
quantifi
chang
antivir
antibodi
repertoir
adapt
recent
report
zscore
base
algorithm
pairwis
differenti
quantif
peptid
enrich
chang
antibodi
bind
time
consid
signific
initi
versu
day
pairwis
zscore
greater
fig
show
result
one
patient
pairwis
virscan
analysi
pairwis
enrich
peptid
viral
speci
intend
repres
provid
supplement
tabl
nucleic
acid
test
previous
diagnos
herp
simplex
viru
infect
individu
consist
predomin
enrich
peptid
design
repres
alphaherpesvirusassoci
protein
notabl
antibodi
patient
enceph
enrich
peptid
design
repres
highlight
potenti
crossreact
antivir
antibodi
virscan
librari
design
repres
protein
human
virom
amino
acid
peptid
tile
adjac
tile
overlap
amino
acid
due
design
overlap
well
presenc
homolog
peptid
relat
virus
wide
rang
epitop
redund
exist
within
librari
simpl
preliminari
model
assum
two
peptid
share
exact
sequenc
least
seven
amino
acid
long
could
potenti
recogn
monoclon
antibodi
convers
two
peptid
enrich
share
seven
amino
acid
sequenc
assum
bind
due
least
two
uniqu
antibodi
clone
therefor
construct
databas
seven
amino
acid
overlap
among
peptid
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
virscan
librari
set
enrich
peptid
databas
use
construct
network
graph
peptid
repres
node
overlap
sequenc
repres
edg
connect
node
given
network
enrich
peptid
devis
iter
method
remov
peptid
maxim
subset
unconnect
peptid
remain
number
remain
peptid
repres
minimum
number
nonredund
antibodi
specif
requir
produc
network
therefor
consid
conserv
estim
antibodi
respons
breadth
order
iter
disconnect
graph
remov
connect
peptid
one
time
tie
broken
favor
retent
strongli
enrich
peptid
base
assumpt
peptid
like
harbor
cognat
versu
cross
reactiv
epitop
process
describ
method
final
set
nonoverlap
independ
peptid
select
network
use
approach
denot
solid
outlin
fig
also
examin
largest
connect
subgraph
virus
peptid
design
repres
fig
assess
potenti
unintend
select
bia
graph
disconnect
approach
inadvertantli
favor
lower
align
score
weaker
enrich
perform
two
mannwhitney
u
test
detect
signific
differ
zscore
align
score
set
select
nonoverlap
peptid
versu
set
peptid
discard
network
disconnect
align
score
plot
versu
zscore
fig
enrich
peptid
zero
connect
consid
analysi
unaffect
iter
method
test
reach
signific
twotail
pvalu
respect
suggest
method
nonoverlap
peptid
select
significantli
bia
zscore
align
score
select
peptid
pairwiseenrich
peptid
nonoverlap
peptid
select
way
analysi
previou
studi
virscan
peptid
defin
simpli
specif
viral
protein
intend
repres
howev
order
exhaust
consid
sequenc
similar
thu
potenti
antibodi
cross
reactiv
construct
comprehens
genom
databas
known
human
viral
speci
exclud
potenti
open
read
frame
orf
annot
bia
virscan
peptid
sequenc
align
via
tblastn
protein
sequenc
databas
form
translat
viral
genom
read
frame
relationship
virscan
peptid
human
virus
thu
repres
matrix
align
bit
score
fig
contrast
design
nonoverlap
enrich
peptid
versu
align
matrix
number
peptid
align
one
singl
viru
also
report
note
consider
peptideviru
align
enabl
possibl
detect
infect
involv
virus
explicitli
repres
virscan
librari
design
eg
macacin
alphaherpesviru
refer
databas
updat
thu
possibl
new
infect
may
identifi
reanalyz
exist
datath
matrix
align
bitscor
associ
enrich
nonoverlap
peptid
provid
cluster
heatmap
fig
fig
illustr
enrich
nonoverlap
peptid
align
multipl
virus
also
appar
align
share
among
human
alphaherpesvirus
expect
given
diagnos
infect
howev
almost
everi
singl
peptid
align
alphaherpesviru
align
use
binomi
test
calcul
probabl
fraction
select
peptid
among
select
peptid
would
occur
null
model
defin
fraction
represent
peptid
entir
virscan
librari
fig
way
modul
use
rank
order
potenti
infect
signific
prepar
next
stage
analysi
implement
modul
result
increas
sensit
decreas
specif
detect
infect
associ
independ
enrich
peptid
possibl
viral
infect
goal
modul
weigh
evid
infect
given
relationship
enrich
peptid
virus
initi
signific
viru
virusi
determin
modul
iter
compar
virus
also
share
peptid
align
virusj
number
share
nonshar
peptid
separ
evalu
signific
use
binomi
test
describ
method
three
possibl
outcom
virusivirusj
comparison
illustr
fig
number
nonshar
virusiassoci
peptid
signific
number
nonshar
virusjassoci
peptid
signific
suggest
enrich
share
peptid
like
attribut
infect
virusi
case
peptid
align
virus
longer
associ
virusj
ii
number
nonshar
peptid
signific
virus
suggest
uniqu
align
share
enrich
attribut
infect
virusi
virusj
case
share
peptid
remain
associ
virus
iii
number
share
peptid
signific
number
nonshar
peptid
associ
either
viru
alon
signific
scenario
assum
enrich
like
due
true
infect
insuffici
evid
distinguish
whether
infect
origin
either
virus
case
share
peptid
align
remain
share
virus
assign
tag
indic
infect
could
distinguish
iter
probabilist
assess
share
peptideviru
associ
enrich
peptid
associ
exclus
virusi
remov
consider
updat
pvalu
calcul
remain
viru
process
iter
viru
pair
share
peptid
align
analyz
upon
complet
modul
therefor
conserv
remov
fals
posit
viral
associ
retain
peptid
associ
like
caus
infect
includ
indistinguish
infect
avarda
framework
use
analyz
longitudin
data
appli
addit
set
encephalit
patient
potenti
viral
etiolog
eight
receiv
diagnos
viral
infect
base
clinic
nucleic
acid
test
remaind
undiagnos
treat
potenti
viral
enceph
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
summar
find
provid
tabl
use
avarda
threshold
requir
least
three
independ
enrich
peptid
pbh
identifi
statist
signific
extant
viral
infect
nine
patient
pairwis
virscan
data
set
provid
fig
similar
avarda
analysi
encephalit
patient
suspect
viral
enceph
result
singl
signific
infect
interestingli
infect
bare
exceed
threshold
three
align
independ
peptid
rel
weak
pbh
four
nine
case
diagnos
confirm
nucleic
acid
test
correspond
precis
infect
indic
avarda
result
discord
howev
pcr
base
diagnosi
cytomegaloviru
cmv
versu
avarda
determin
roseolaviru
infect
x
independ
peptid
enrich
pbh
closer
investig
clinic
histori
reveal
previou
ganciclovir
treatment
cmv
infect
suggest
long
term
prior
infect
consist
avarda
detect
signific
cmv
antibodi
day
reactiv
differenti
unchang
time
clinic
antibodi
test
agre
result
avarda
measur
increas
igg
convalesc
serum
remain
four
patient
diagnos
hsv
enteroviru
varicellazost
viru
vzv
fig
fig
respect
none
signific
pairwis
chang
detect
avarda
two
week
period
fig
singl
timepoint
avarda
analys
clinic
antibodi
test
detect
high
unchang
viru
specif
igg
level
suggest
either
chronic
preexist
infect
potenti
unrel
enceph
ii
patient
initi
sera
collect
late
cours
diseas
see
differenti
chang
iii
virscan
detect
chang
antibodi
specificitiestit
clinic
antibodi
test
detect
increas
vzvspecif
igg
level
detect
avarda
investig
virscan
result
howev
reveal
sever
vzv
align
peptid
appear
differenti
enrich
threshold
indic
default
threshold
may
stringent
case
fig
individu
undiagnos
enceph
avarda
identifi
signific
infect
cmv
epsteinbarr
viru
ebv
enteroviru
confirmatori
clinic
serolog
detect
increas
viral
igg
two
case
cmv
ebv
could
confirm
avarda
find
howev
potenti
due
limit
avail
serum
dilut
prior
test
addit
unabl
conduct
clinic
serolog
test
enteroviru
igg
due
insuffici
serum
volum
pathophysiolog
sequella
infecti
diseas
believ
contribut
mani
human
ill
includ
autoimmun
eg
type
diabet
neurodegen
diseas
eg
alzheim
diseas
cancer
eg
cervic
cancer
allerg
diseas
eg
asthma
longitudin
cohort
studi
provid
import
epidemiolog
approach
causal
link
environment
exposur
viral
infect
pre
clinic
outcom
assess
util
virscanavarda
set
profil
serum
sampl
collect
longitudin
everi
two
six
month
atrisk
individu
prior
onset
type
diabet
tabl
summar
result
avarda
analys
one
studi
particip
across
avail
time
point
month
year
age
avarda
detect
infect
includ
respons
immun
met
signific
criteria
time
cours
fig
includ
adenoviru
enteroviru
parechoviru
rhinoviru
influenza
noroviru
parainfluenza
viru
metapneumoviru
respiratori
syncyti
viru
coronaviru
astroviru
infect
antibodi
direct
measl
rubella
mump
detect
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
first
interv
mmr
vaccin
administ
year
age
fig
also
highlight
longitudin
behavior
peptid
parechoviru
found
differenti
enrich
comparison
sera
obtain
versu
year
age
type
peptidelevel
analysi
use
character
epitop
specif
tempor
antibodi
respons
subset
may
persist
due
format
long
live
plasma
cell
sensit
detect
infect
may
diminish
infrequ
sampl
due
transient
natur
humor
respons
ii
increas
level
interrelationship
among
differenti
enrich
set
peptid
iii
lump
sequenti
infect
relat
virus
therefor
assess
impact
sampl
frequenc
infect
detect
sensit
select
perform
pairwis
analys
across
differ
sampl
interv
observ
number
detect
infect
decay
decreas
sampl
frequenc
fig
design
longitudin
studi
includ
comprehens
antibodi
analys
take
find
consider
diagnost
epidemiolog
util
antibodi
analys
limit
larg
part
due
difficulti
account
antibodi
cross
reactiv
among
close
relat
organ
develop
analyt
framework
account
potenti
cross
reactiv
panvir
serolog
data
provid
probabilist
assess
infect
therefor
import
advanc
current
studi
demonstr
avarda
appli
virscan
analysi
longitudin
collect
serum
sampl
reliabl
identifi
evolv
igg
respons
specif
virus
examin
perform
avarda
diagnos
viral
enceph
set
often
challeng
yet
critic
distinguish
infecti
autoimmun
etiolog
panvir
igg
analysi
may
provid
inform
complementari
nucleic
acid
test
thu
improv
diagnost
sensit
low
abund
unexpect
virus
distinguish
activ
latent
infect
studi
combin
virscanavarda
analysi
tradit
diagnost
method
increas
rate
diagnosi
panvir
igm
analys
explor
may
also
inform
differenti
new
recurr
exposur
despit
expand
util
viral
antibodi
test
virscanavarda
still
limit
requir
develop
adapt
immun
respons
take
valuabl
time
may
occur
patient
suppress
immun
system
propos
four
gener
area
futur
iter
avarda
could
effect
incorpor
virscan
inform
first
peptid
enrich
threshold
consid
binari
hit
modul
sinc
degre
enrich
consid
beyond
network
graph
filter
stage
contribut
peptid
final
result
somehow
weight
accord
magnitud
enrich
confid
associ
infect
could
potenti
calcul
accur
second
strength
peptideviru
align
quantifi
bitscor
similarli
consid
avarda
incorpor
quantit
measur
might
also
improv
final
result
third
enrich
set
peptid
share
sevenamino
acid
sequenc
current
treat
singl
antibodi
specif
howev
confid
associ
enrich
overlap
peptid
gener
higher
peptid
enrich
isol
modul
attribut
greater
confid
peptid
cluster
sensit
avarda
may
increas
particularli
infect
elicit
restrict
respons
addit
avarda
may
benefit
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
nuanc
consider
overlap
peptid
versu
current
simpl
requir
perfect
match
overlap
fourth
may
possibl
develop
statist
test
distinguish
among
infect
current
found
indistinguish
avarda
one
envis
pairwis
comparison
homolog
peptid
might
discern
like
two
highli
relat
speci
even
strain
consist
prefer
antibodi
recognit
one
organ
peptid
anoth
approach
success
would
enabl
expand
taxonom
refer
databas
beyond
viru
speci
level
potenti
enhanc
specif
avarda
even
speci
level
avarda
frequent
distinguish
highli
interrel
virus
particularli
enterovirus
adenovirus
experi
expect
improv
contempl
markedli
improv
perform
futur
version
avarda
investig
potenti
loss
sensit
due
network
graph
filter
modul
execut
avarda
without
invok
step
previous
avardadetect
infect
exhibit
nine
increas
rubella
viru
peptid
enrich
six
increas
herpesviru
peptid
enrich
fig
clinic
serolog
analysi
detect
slight
though
insignific
increas
rubella
viru
antibodi
titer
timepoint
highlight
potenti
loss
sensit
due
remov
overlap
peptid
insuffici
serum
prevent
clinic
test
human
herpesviru
antibodi
patient
conceptu
paradigm
underli
avarda
may
find
applic
beyond
analysi
virscan
data
studi
involv
librari
redund
potenti
antibodi
cross
reactiv
algorithm
modul
may
enabl
deconvolut
data
instanc
librari
bacteri
parasit
fungal
pathogen
peptidom
may
analyz
analog
virscan
data
screen
ige
antibodi
librari
allergenderiv
peptid
may
present
similar
challeng
due
share
epitop
across
relat
organ
addit
incorpor
conceptu
framework
avarda
design
peptid
librari
may
enhanc
ultim
discriminatori
power
beyond
peptid
librari
screen
fulllength
protein
librari
screen
eg
via
protein
microarray
plato
etc
may
also
benefit
avarda
consider
share
sequenc
potenti
crossreact
furthermor
phipseq
analysi
human
proteom
perform
conjunct
virscan
set
undiagnos
enceph
exampl
combin
human
proteom
panvir
analysi
could
prove
particularli
inform
bayesian
interpret
join
data
set
could
potenti
perform
assumpt
either
autoimmun
viral
infect
bacteri
infect
etc
may
improv
diagnost
sensit
incorpor
avarda
clinic
diagnosi
andor
interpret
epidemiolog
studi
therefor
like
becom
import
tool
link
human
health
environment
exposur
diabet
auto
immun
studi
young
daisi
prospect
studi
children
increas
risk
type
diabet
detail
newborn
screen
follow
previous
publish
per
protocol
serum
test
month
autoantibodi
neg
annual
thereaft
children
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
found
autoantibodi
posit
retest
everi
month
recruit
took
place
followup
result
avail
februari
written
inform
consent
obtain
parent
studi
particip
colorado
multipl
institut
review
board
approv
studi
protocol
singapor
neurolog
infect
program
snip
prospect
cohort
approv
singhealth
centralis
instituit
review
board
cirb
ref
snip
studi
aim
describ
epidemiolog
cn
infect
singapor
improv
diagnosi
etiolog
cn
infect
systemat
clinic
laboratori
neuroradiolog
evalu
extens
diagnost
test
evalu
prognosi
longterm
outcom
socioeconom
cost
cn
infect
establish
archiv
biolog
tissu
patient
enceph
cn
infect
util
futur
test
emerg
pathogen
noninfecti
etiolog
subject
enrol
hospit
singapor
singapor
gener
hospit
tan
tock
seng
hospit
nation
univers
health
system
changi
gener
hospit
khoo
teck
puat
hospit
kandang
kerbau
hospit
individu
male
femal
one
month
age
enrol
upon
admiss
hospit
clinic
suspicion
cn
infect
one
follow
fever
histori
fever
present
ill
seizur
focal
neurolog
deficit
csf
white
cell
count
pleocytosi
wbcul
abnorm
neuroimag
suggest
cn
infect
abnorm
electroencephalogram
suggest
cn
infect
depress
alter
level
conscious
altern
etiolog
acut
paralysi
identifi
patient
indwel
ventricular
devic
evd
ventriculoperiton
shunt
exclud
studi
blood
sampl
obtain
enrol
studi
week
enrol
time
discharg
virscan
screen
perform
describ
previous
briefli
use
midcopi
bacteriophag
display
librari
span
human
virom
consist
peptid
tile
overlap
adjac
tile
e
coli
novagen
use
expand
librari
store
dmso
elisa
use
quantifi
igg
serum
concentr
use
southern
biotech
captur
detect
antibodi
cat
respect
next
igg
mix
ml
virscan
librari
concentr
pfu
dilut
pb
reaction
follow
overnight
endoverend
rotat
phage
serum
mixtur
protein
ag
coat
magnet
bead
invitrogen
catalog
number
ad
reaction
g
rotat
addit
h
later
bead
wash
three
time
resuspend
herculas
ii
polymeras
agil
cat
pcr
master
mix
use
bravo
agil
liquid
handl
robot
mix
underw
cycl
pcr
subsequ
amplifi
product
underw
addit
cycl
pcr
sampl
specif
barcod
illumina
sequenc
adapt
ad
product
pool
sequenc
use
illumina
hiseq
rapid
mode
cycl
singl
end
read
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
sequenc
read
count
virscan
peptid
normal
sampl
sequenc
depth
nrc
robust
regress
top
abund
day
nrc
use
calcul
expect
day
nrc
addit
sampl
well
plate
contain
well
without
antibodi
input
mock
ip
serv
provid
expect
background
signal
singl
timepoint
analys
sampl
also
use
calcul
expect
standard
deviat
peptid
given
nrc
pairwis
analys
observ
day
nrc
minu
expect
day
nrc
peptid
residu
normal
expect
standard
deviat
order
calcul
pairwis
zscore
day
versu
day
nrc
scatter
plot
gener
r
two
case
fail
qualiti
control
filter
due
poor
day
versu
day
correl
therefor
analysi
peptideviru
align
tabl
creat
follow
first
viral
genom
includ
repres
genom
refseq
neighbor
strain
refseq
download
may
genbank
format
ncbi
viral
genom
resourc
host
field
genbank
file
host
column
ncbi
viral
genom
resourc
neighbor
file
use
find
viral
strain
infect
human
furthermor
virus
annot
human
host
viralhost
databas
includ
humanhost
annot
propag
viral
strain
strain
speci
blast
databas
nucleotid
sequenc
human
virus
creat
use
makeblastdb
sequenc
organ
speci
level
tblastn
run
creat
peptideviru
align
tabl
paramet
outfmt
seg
maxhsp
softmask
fals
wordsiz
maxtargetseq
avarda
develop
implement
python
depend
packag
numpi
panda
networkx
scipi
statsmodel
softwar
read
file
zscore
peptid
sampl
output
list
signific
viral
infect
along
associ
pvalu
assign
count
peptid
viru
relev
inform
use
analysi
avarda
download
gener
use
githubcomlarmanlabavarda
document
provid
readm
defin
maxim
set
nonoverlap
antibodi
specif
describ
modul
section
databas
seven
amino
acid
overlap
peptid
virscan
librari
use
construct
undirect
network
graph
node
repres
enrich
peptid
edg
repres
overlap
least
sevenamino
acid
stretch
share
link
peptid
goal
remov
connect
within
graph
iter
delet
peptid
peptid
maximum
connect
degre
graph
remov
first
degre
remain
peptid
recalcul
multipl
peptid
equival
maximum
degre
within
graph
share
edg
rank
enrich
zscore
minimum
zscore
peptid
remov
first
process
repeat
max
degre
peptid
left
graph
two
point
remain
graph
structur
cycl
end
peptid
path
two
end
peptid
isol
singl
peptid
cycl
peptid
lowest
zscore
remov
first
result
path
path
peptid
number
start
one
end
even
number
peptid
remov
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
path
oddnumb
length
path
evennumb
length
split
remov
peptid
lowest
zscore
result
path
oddnumb
length
anoth
path
evennumb
length
process
iter
edg
remain
null
probabl
binomi
test
describ
modul
compar
set
enrich
peptid
associ
viru
use
binomi
test
determin
signific
associ
null
model
assum
peptid
align
viru
randomli
drawn
virscan
librari
viru
least
one
enrich
peptid
align
perform
binomi
test
use
n
total
number
enrich
hit
k
hit
align
virusi
null
probabl
f
total
number
peptid
align
virusi
divid
total
number
peptid
virscan
librari
pair
virus
share
enrich
peptid
align
evalu
follow
first
binomi
test
perform
nonshar
uniqu
peptid
order
weigh
evid
distinguish
infect
test
f
number
peptid
align
virusi
virusj
length
libraryshar
align
virusi
virusj
similarli
n
number
enrich
hitsshar
virusi
j
hit
second
binomi
test
perform
share
indistinguish
peptid
align
f
share
virusi
j
align
length
libraryuniqu
align
virusiuniqu
align
virusj
determin
signific
set
pvalu
threshold
p
requir
total
number
peptid
align
k
paramet
adjust
depend
desir
stringenc
analysi
viral
comparison
share
align
remov
indistinguish
tag
n
first
initi
number
enrich
nonoverlap
peptid
virus
rank
order
signific
base
binomi
test
viru
enrich
peptid
align
next
signific
viru
compar
everi
viru
share
peptid
align
comparison
either
viru
found
statist
signific
number
nonshar
peptid
share
align
remov
latter
viru
case
fig
virus
found
statist
signific
number
nonshar
peptid
share
align
remain
associ
virus
thu
contribut
signific
infect
case
ii
fig
neither
viru
found
statist
signific
number
nonshar
peptid
binomi
test
perform
share
peptid
determin
whether
suffici
evid
infect
least
one
two
virus
virus
signific
number
share
align
numer
indistinguish
tag
annot
result
indic
algorithm
unabl
accur
distinguish
infect
one
virus
case
iii
fig
pairwis
comparison
signific
viru
complet
viru
remov
consider
n
decreas
number
peptid
uniqu
assign
viru
procedur
updat
n
thu
remov
peptid
associ
signific
infect
consider
subsequ
test
peptid
use
null
model
pvalu
remain
viru
recalcul
new
top
rank
virusi
select
next
round
comparison
virusij
pair
evalu
final
pvalu
infect
adjust
multipl
hypothesi
correct
order
consid
multipl
hypothesi
test
infect
ancillari
relev
data
also
print
file
herp
simplex
viru
varicella
zoster
viru
cytomegaloviru
epsteinbarr
viru
antibodi
test
carri
diasorin
use
chemiluminesc
immunoassay
technolog
john
hopkin
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
patholog
core
facil
serolog
analys
perform
quest
diagnost
human
herpesviru
antibodi
analyz
via
immunofluoresc
assay
technolog
human
parainfluenza
virus
antibodi
analyz
via
complement
test
enteroviru
test
done
due
larg
volum
sera
requir
per
test
due
limit
avail
serum
sampl
dilut
prior
test
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
peptid
align
heatmap
figur
remov
align
determin
crossreact
c
bar
graph
pvalu
viru
consider
crossreact
use
modul
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
tabl
plot
indic
virscan
normal
read
count
day
dataset
xaxi
plot
day
dataset
yaxi
robust
linear
regress
line
drawn
scatterplot
point
blue
repres
peptid
enrich
pairwis
zscore
enrich
peptid
associ
signific
infect
determin
avarda
addit
mark
red
cross
scatterplot
provid
fig
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
figur
avarda
analysi
pairwis
enrich
score
one
patient
sera
collect
longitudin
scatterplot
al
correspond
consecut
pairwis
time
interv
month
year
age
signific
infect
identifi
avarda
detail
tabl
robust
linear
regress
line
drawn
scatterplot
point
blue
repres
peptid
enrich
pairwis
zscore
enrich
peptid
associ
parechoviru
infect
determin
avarda
b
addit
mark
red
cross
plot
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
tabl
summari
avarda
result
enceph
cohort
viru
column
indic
identifi
viral
infect
via
avarda
nucleic
acid
test
total
sampl
hit
total
filter
sampl
hit
refer
number
total
pairwis
enrich
peptid
number
enrich
peptid
independ
filter
modul
assign
count
indic
number
enrich
peptid
associ
signific
infect
avarda
analys
raw
pvalu
bh
pvalu
column
repres
origin
multipl
hypothesi
test
correct
avarda
signific
valu
respect
nucleic
acid
serolog
test
result
indict
last
two
column
indic
specif
test
conduct
avarda
also
identifi
ebv
infect
pbh
b
infect
indistinguish
identifi
report
hpiv
share
indistinguish
tag
bovin
respiroviru
enteroviru
infect
share
indistinguish
tag
enterovirus
c
h
rhinoviru
c
indic
serolog
test
detect
viru
specif
igg
unchang
timepoint
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
tabl
avarda
result
one
individu
longitudin
collect
sera
viru
column
indic
viral
infect
identifi
avarda
age
interv
infect
column
refer
patient
age
interv
given
infect
identifi
infect
identifi
two
consecut
time
interv
consid
infect
interv
infect
merg
total
sampl
hit
total
filter
sampl
hit
column
provid
number
total
pairwis
enrich
peptid
number
enrich
peptid
implement
modul
assign
count
indic
number
enrich
peptid
associ
signific
infect
avarda
analys
raw
pvalu
bh
pvalu
column
repres
origin
multipl
hypothesi
test
correct
avarda
signific
valu
respect
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
copyright
holder
preprint
peerreview
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
